Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study.

This trend did not reach statistical significance ( P = 0.250), which may be attributable to the limited sample size and increased cumulative toxicity associated with prolonged therapy (Figs. 3 C-D).In a further comparison between the NC and SC-HD groups, although the SC-HD group demonstrated superior 2-year RFS ( P = 0.021), no significant difference in 2-year OS was observed ( P = 0.129) (Fig. 3 E-F).

also in 111,027 other papers

In contrast, the LC group showed no significant survival benefit with higher cytarabine doses, despite a numerical trend toward better RFS in the ID subgroup (84.0% vs. 63.6–71.1%).

also in 1,012 other papers